Torrent Pharmaceuticals Q1 FY27: net profit up 3% to ₹566 crore, revenue up 55%
Torrent Pharmaceuticals (TORNTPHARM) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹4,921 crore (+54.8% year on year), net profit of ₹566 crore (+3.3%), earnings per share of ₹14.87. The company is valued at about ₹1.72 lakh…
What happened
Torrent Pharmaceuticals (TORNTPHARM) told the exchanges on 23 October 2026 at 04:30 PM that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹4,921 crore (+54.8% year on year), net profit of ₹566 crore (+3.3%), earnings per share of ₹14.87.
Company snapshot
Torrent Pharmaceuticals is a large-cap company in the Healthcare sector, with a market value of about ₹1.72 lakh crore.
The stock last traded at ₹4,524.4, against a 52-week range of ₹3,532.6–₹5,250 (13.8% below the high).
Before this filing the shares had moved −5.9% over the month and −9.5% over three months. Average daily turnover over the last 20 sessions was about ₹152 crore.
Promoters held 60.78% at the end of Q2 FY27, down 7.53% points from the previous quarter. Foreign institutions owned 17.97% and domestic institutions 12.87%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,178 | 548 | 16.19 |
| Q2 FY26 | 3,302 | 591 | 17.45 |
| Q3 FY26 | 3,303 | 635 | 18.77 |
| Q4 FY26 | 4,197 | 389 | 11.51 |
| Q1 FY27 | 4,921 | 566 | 14.87 |
What history shows
This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.9% over five days; 54% of them rose the next day.
Market-wide, 9,702 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 23 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Torrent Pharmaceuticals accepts resignation of Executive Director Amal Kelshikar
- TORNTPHARM Outlook for the Week
- Who is Amal Kelshikar? Why did he resign from the position of Torrent Pharmaceuticals' Executive Director? Explained
- Torrent Pharmaceuticals Share Price Gains on Market Action
- Torrent accepts Kelshikar resignation: October 23 call for Torrent Pharmaceuticals stock
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.